From records to reasoning in minutes
All case states covered. Patient-specific reasoning for each.
Seven outer states plus five clinical substates cover the full clinical picture — metastatic, curative-intent, and treatment-eligibility tracks. Driver-positive cases route into one of 117 terminal buckets; driver-negative cases route through chemo-immunotherapy pathways stratified by histology and PD-L1.
Patient is on active therapy with documented response. Monitoring and toxicity management are the clinical priority.
Active therapy with stable or indeterminate response. Structured monitoring protocol in effect.
Confirmed progression on prior line. A targeted next-line option is available based on resistance profiling.
Confirmed progression with no standard targeted option. Clinical trial enrollment is the primary recommendation pathway.
Isolated site(s) of progression while systemic disease remains controlled. Local ablation may extend systemic therapy duration.
No prior systemic therapy. First-line treatment selection based on driver, PD-L1 expression, and disease burden.
Post-curative-resection patient on adjuvant therapy. Continuation per ADAURA / IMpower010 / KEYNOTE-091 with surveillance imaging — distinct logic tree from metastatic monitoring.
Five clinical contexts modeled beneath the outer states — including driver-negative disease and curative-intent tracks.
- Neoadjuvant / perioperative active treatment
- Unresectable stage III / consolidation
- Post-curative recurrence
- No actionable driver / immunotherapy-chemo pathway
- Best supportive care / treatment-ineligible
121 terminal route buckets across 11 driver families.
Each driver carries its own route buckets covering 1L, resistance, bypass amplification, transformation, stage III, and adjuvant contexts. Driver-negative cases route through a parallel chemo-immunotherapy lane stratified by histology and PD-L1.
Validated against 175 gold-standard cases across 11 case groups, including 15 adversarial safety-gate scenarios that block contraindicated recommendations — e.g., IO monotherapy in EGFR-positive disease, or platinum doublets in PS≥3 patients.
All the prevailing, industry-standard oncology evidence —
combined into a single reasoning trail.
Recommendations cite the source for every claim — guidelines, regulatory labels, pivotal trials, peer-reviewed publications, and late-breaking abstracts — woven together so the rationale is auditable end-to-end.
This should compress work, not add it.
We're early — no clinician testimonials yet. But the engine is built around three concrete moments in the clinical workflow, and the value compounds at each one.
Pre-visit
Engine output ready before the patient walks in. Structured summary, options, trial matches — already organized. The 20-minute slot starts with the thinking already done.
At decision points
Post-progression. Atypical drivers. Resistance configurations. Co-mutation contexts that change sequencing. The cases where you want to make sure nothing was missed — across every major NSCLC driver, every resistance pathway, every case state.
Around trials
Trial relevance surfaced contextually within the treatment decision — not as a separate research task. The right trial, at the right moment, with eligibility already screened against the chart.
Ready to see it on your cases?
Request access and we'll onboard your institution within 48 hours. No integration required — just your clinical records.